Want to see IN:SPARC full AI Analyst Report?
SPARC Stock Chart & Stats
₹135.70
-₹2.58(-1.32%)
At close: 4:00 PM EST
₹135.70
-₹2.58(-1.32%)
Day’s Range― - ―
52-Week Range₹108.20 - ₹252.95
Previous CloseN/A
Volume383.41K
Average Volume (3M)24.00K
Market Cap
₹77.61B
Enterprise Value₹83.34B
Total Cash (Recent Filing)₹30.00M
Total Debt (Recent Filing)₹4.17B
Price to Earnings (P/E)5.0
Beta1.79
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.23
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.78
Price to Sales (P/S)1.98
P/FCF Ratio-12.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Out-licensing / Milestone-driven Revenue ModelA partner-led, milestone-and-royalty business model lets SPARC advance assets without full commercialization capital, preserving cash and offering scalable upside as candidates hit development and approval milestones. Structurally this reduces fixed-cost exposure and leverages partners' commercial capabilities over time.
Sharp FY2026 Revenue And Profitability ReboundThe material step-up in FY2026 revenue and reported profitability indicates SPARC can generate significant program-related income (deals or milestones) that materially move the financials. If repeatable, such step-changes can transform cash flow dynamics and strengthen negotiating leverage with partners over the medium term.
Improved Leverage Metrics In FY2026Lower reported leverage in FY2026 provides greater balance-sheet flexibility to support ongoing R&D programs or bridge financing needs. A manageable debt-to-equity ratio reduces near-term refinancing risk and improves capacity to structure partnership deals or secure development financing without immediate distress.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent cash burn (OCF and FCF negative each year, OCF -2.73B and FCF -2.97B in FY2026) signals weak internal cash generation and creates ongoing funding needs. Over months, this elevates dilution or debt financing risk and undermines the durability of reported earnings absent sustained cash conversion or recurring partner payments.
Volatile Multi-year Earnings And MarginsA history of multi-year losses and swinging margins increases execution and forecasting risk for SPARC. Such volatility can deter long-term partners, complicate budgeting for expensive clinical programs, and means FY2026 results may be driven by one-off items rather than sustainable operational improvement.
History Of Negative Equity And Balance-sheet StrainEpisodes of negative equity reflect past capital erosion and higher financial stress, implying potential vulnerability to adverse outcomes. Structurally this raises the likelihood of future dilution, constrained access to low-cost financing, and weaker bargaining power in partner deals if additional capital injections become necessary.
Sun Pharma Advanced Research Co. Ltd. News
SPARC FAQ
What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹108.20 and its highest was ₹252.95 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹77.61B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 36 days.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on May 18, 2026. The company reported ₹54.27 earnings per share for the quarter, beating the consensus estimate of N/A by ₹54.27.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of ₹54.27 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.886%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited (SPARC), a biopharmaceutical firm established in Mumbai, India, in 2006 and operating as a subsidiary of Shanghvi Finance Private Limited, is globally committed to the discovery and advancement of innovative pharmaceutical products. The company's strategic focus involves developing novel chemical and biological entities, as well as improving existing formulations, with a key therapeutic emphasis on conditions within oncology, neurodegeneration, ophthalmology, and dermatology. SPARC currently commercializes Elepsia, a specialized levetiracetam formulation for managing epilepsy, and Xelpros, a latanoprost ophthalmic emulsion prescribed for the treatment of open-angle glaucoma or ocular hypertension. Its robust development pipeline showcases numerous candidates in various clinical trial stages: SDN-037, a difluprednate formulation in Phase 3 for addressing inflammation and pain linked to ocular surgery; PDP-716, also in Phase 3 for glaucoma; and phenobarbital sodium, targeting neonatal seizures. Additionally, the company is progressing Vodobatinib (SCO-088), which has concluded Part A of its Phase 1 study for resistant chronic myelogenous leukemia, and Vodobatinib (SCC-138), currently in Phase 2 for Parkinson's disease. Other pipeline assets include SCD-044, a Phase 2 candidate for psoriasis and atopic dermatitis, and SCO-120, advancing through Phase 1 for hormone receptor-positive, HER2-negative, metastatic breast cancer. Complementing its internal efforts, SPARC engages in strategic collaborations, including one with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders, and another with HitGen Ltd. aimed at identifying promising small molecule leads for selected therapeutic targets.
Technical Analysis
Jubilant Pharmova Limited
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Suven Life Sciences Limited
―
Suven Pharmaceuticals Ltd.
―